Actively Recruiting

Phase 2
Age: 0Months - 36Months
All Genders
NCT07126262

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

Led by BioMarin Pharmaceutical · Updated on 2026-03-31

60

Participants Needed

26

Research Sites

152 weeks

Total Duration

On this page

Sponsors

B

BioMarin Pharmaceutical

Lead Sponsor

I

ICON Clinical Research

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period.

CONDITIONS

Official Title

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

Who Can Participate

Age: 0Months - 36Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be 0 to less than 36 months old at randomization
  • Confirmed genetic diagnosis of hypochondroplasia via whole genome sequencing showing FGFR3 pathogenic variant
  • Participants aged 0 to less than 12 months must have a height Z-score of 64; -1.0 SDS
  • Participants aged 12 to less than 36 months must have a height Z-score of 64; -2.0 SDS
  • Participant's weight at Day 1 visit must be at least 3 kilograms
Not Eligible

You will not qualify if you...

  • Short stature conditions other than hypochondroplasia (e.g., achondroplasia, trisomy 21, pseudoachondroplasia)
  • Unstable medical conditions likely requiring surgical intervention during the study
  • Taking any prohibited medications
  • Treated with growth hormone, IGF-1, or anabolic steroids in the 6 months prior to screening or long-term treatment (> 3 months) at any time
  • Need for any investigational agent before study completion
  • Received another investigational product or device within 30 days prior to screening
  • Used investigational products or devices for hypochondroplasia or short stature treatment at any time
  • Current or history of malignancy, or under evaluation for suspected malignancy
  • Known hypersensitivity to vosoritide or its ingredients
  • Conditions or circumstances that increase risk for poor treatment adherence or study completion
  • Concurrent diseases or conditions interfering with participation or safety assessments

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 26 locations

1

Phoenix Children's Hospital - Thomas Campus (Main)

Phoenix, Arizona, United States, 85016

Actively Recruiting

2

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Not Yet Recruiting

3

Benioff Children's Hospital - Oakland

Oakland, California, United States, 94609

Actively Recruiting

4

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

Actively Recruiting

5

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

6

The Johns Hopkins University School of Medicine

Baltimore, Maryland, United States, 21205

Actively Recruiting

7

University of Minneasota Masonic Children's Hospital

Minneapolis, Minnesota, United States, 55454

Actively Recruiting

8

University of Missouri

Columbia, Missouri, United States, 65211

Actively Recruiting

9

Cook Children's Endocrinology

Fort Worth, Texas, United States, 76104

Not Yet Recruiting

10

Children's Wisconsin - Fox Valley Hospital

Neenah, Wisconsin, United States, 54956

Not Yet Recruiting

11

Children's Health Queensland Hospital and Health Service

South Brisbane, Queensland, Australia, 4101

Not Yet Recruiting

12

Royal Children's Hospital Melbourne

Parkville, Victoria, Australia, 3052

Actively Recruiting

13

Hôpital Bicêtre

Le Kremlin-Bicêtre, Paris, France, 94270

Actively Recruiting

14

Hospices Civils de Lyon - Hôpital Femme Mère Enfant

Bron, Rhone-Alps, France, 69500

Not Yet Recruiting

15

Uniklinik Köln

Cologne, North Rhine-Westphalia, Germany, 50937

Actively Recruiting

16

Universitätsklinikum des Saarlandes

Homburg, Saarland, Germany, 66421

Actively Recruiting

17

Universitätskinderklinik Magdeburg

Magdeburg, Saxony-Anhalt, Germany, 39120

Not Yet Recruiting

18

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Rome, Italy, 00168

Not Yet Recruiting

19

IRCCS Istituto Giannina Gaslini

Genova, Italy, 16147

Actively Recruiting

20

Kumamoto University Hospital

Kumamoto, Japan, 860-8556

Actively Recruiting

21

Osaka Women's and Children's Hospital

Osaka, Japan, 94-1101

Actively Recruiting

22

Institute of Science Tokyo Hospital

Tokyo, Japan, 113-8519

Actively Recruiting

23

Nihon University Itabashi Hospital

Tokyo, Japan, 173-8610

Actively Recruiting

24

Tottori University Hospital

Tottori, Japan, 683-0854

Actively Recruiting

25

Myriad Trials

London, England, United Kingdom, W1W 5DT

Not Yet Recruiting

26

Great Ormond Street Hospital

London, England, United Kingdom, WC1N3BH

Not Yet Recruiting

Loading map...

Research Team

T

Trial Specialist

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months | DecenTrialz